Search clinical trials for: PI3K/mTOR inhibitor,
Total 7770 results
-
Medical College of WisconsinTerminated
-
Merck Sharp & Dohme LLCCompletedAdvanced Breast Cancer | Other Solid Tumors
-
China Medical University HospitalCompleted
-
M.D. Anderson Cancer CenterRigel Pharmaceuticals,Inc.Not yet recruitingMutant IDH1 Inhibitor OlutasidenibUnited States
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompletedHemophilia A or B With InhibitorsCroatia, North Macedonia, Ukraine
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsUnited States
-
Nanjing Medical UniversityCompletedImmune Checkpoint Inhibitor | Endocrine ToxicityChina
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Sun Yat-sen UniversityRecruitingSolid Tumor | Intestinal Flora | Immune Checkpoint InhibitorChina
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
Groupe Hospitalier Paris Saint JosephCompletedProton Pump InhibitorFrance
-
Institut Mutualiste MontsourisRecruitingCancer | Cardiovascular Complication | Immune Checkpoint Inhibitor | Immune-related Adverse EventFrance
-
Institut Mutualiste MontsourisInstitut CurieRecruitingCancer | Immune Checkpoint Inhibitor | Cardiovascular BiomarkersFrance
-
Cancer Institute and Hospital, Chinese Academy...RecruitingSafety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | PertuzumabChina
-
Hellenic Cooperative Oncology GroupCompletedAutoimmune Diseases | Immunotherapy | Checkpoint InhibitorGreece
-
Hoffmann-La RocheChugai PharmaceuticalCompletedHemophilia AKorea, Republic of, United States, France, Germany, Italy, South Africa, Spain, Japan, United Kingdom, Poland, Taiwan, Australia, Costa Rica, New Zealand
-
Ronald BuckanovichGenentech, Inc.RecruitingPARP Inhibitor | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Hedgehog InhibitorUnited States
-
American Thrombosis and Hemostasis NetworkGenentech, Inc.Active, not recruitingHemophilia A With Inhibitor | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
Xiang XieXinjiang Medical UniversityNot yet recruitingCancer | Atherosclerotic Cardiovascular Disease | ASCVD | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
-
Tanta UniversityNot yet recruitingSodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
-
Nanfang Hospital, Southern Medical UniversityRecruitingImmune Checkpoint Inhibitor Associated PneumoniaChina
-
Baxalta now part of ShireBaxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)CompletedAlpha 1-Antitrypsin DeficiencyAustralia, New Zealand
-
Mario Negri Institute for Pharmacological ResearchFederico II University; IRCCS MultimedicaCompletedProton Pump Inhibitor | Primary CareItaly
-
Merck Sharp & Dohme LLCTerminatedColorectal Cancer | Advanced Solid Tumors
-
Jazz PharmaceuticalsCompletedEvaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4 | Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19...United Kingdom
-
PfizerCompletedCarcinoma, Renal Cell | Lymphoma, Mantle-CellSpain
-
Samsung Medical CenterSuspendedAromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea (CYP19)Polymorphism | CYP19 | Aromatase InhibitorKorea, Republic of
-
Radboud University Medical CenterCompletedProton Pump Inhibitor | Inappropriate Drug Use | Discontinuation | E-healthNetherlands
-
Fondation Ophtalmologique Adolphe de RothschildCompletedMEK Inhibitor-Associated Serous RetinopathyFrance
-
Shanghai Chest HospitalBristol-Myers SquibbCompletedNSCLC Stage IV | Checkpoint InhibitorChina
-
Istari Oncology, Inc.Active, not recruiting
-
Bursa Postgraduate HospitalCompletedContrast Agents and Oral Factor Xa InhibitorTurkey
-
Energenx Medical LTD.Recruiting
-
Anne ChangNovartisCompletedBasal Cell CarcinomaUnited States
-
AstraZenecaRecruitingLife Threatening Bleeding | Factor Xa InhibitorJapan
-
Atsushi KawakamiGilead SciencesRecruitingRheumatoid Arthritis | Biomarker | JAK Inhibitor | Musculoskeletal Ultrasound | IL-6 InhibitorJapan
-
Cancer Institute and Hospital, Chinese Academy...Peking University; Peking University Cancer Hospital & InstituteRecruitingMalignant Tumor | Positron Emission Tomography | Fibroblast Activation Protein InhibitorChina
-
University of Kansas Medical CenterRecruitingHMG-CoA Reductase Inhibitor ToxicityUnited States
-
Shanghai Tong Ren HospitalRecruitingEarly PCSK9 Inhibitor on Ventricular RemodlingChina
-
Zhongnan HospitalRecruitingMalignant Neoplasm | PET/CT | Fibroblast Activation Protein InhibitorChina
-
Tianjin Chest HospitalRecruitingAcute Coronary Syndrome | Proprotein Convertase Subtilisin/Kexin Type 9 InhibitorChina
-
Shanghai East HospitalActive, not recruitingAcneiform EruptionsChina
-
Rijnstate HospitalTerminatedCOPD Exacerbation | Enoximone | Phosphodiesterase InhibitorNetherlands
-
Hunan Province Tumor HospitalRecruitingNon-small Cell Lung CancerChina
-
Oregon Health and Science UniversityCompleted
-
Assiut UniversityUnknownProton Pump Inhibitor Allergy
-
Assiut UniversityUnknownProton Pump Inhibitor Allergy
-
Chungbuk National University HospitalCompleted
-
Jules Bordet InstituteCompletedCarcinoma Breast Stage IVBelgium